| Literature DB >> 23750119 |
William J Martin1, Roger I Glass, Houmam Araj, John Balbus, Francis S Collins, Siân Curtis, Gregory B Diette, William N Elwood, Henry Falk, Patricia L Hibberd, Susan E J Keown, Sumi Mehta, Erin Patrick, Julia Rosenbaum, Amir Sapkota, H Eser Tolunay, Nigel G Bruce.
Abstract
Entities:
Mesh:
Substances:
Year: 2013 PMID: 23750119 PMCID: PMC3672215 DOI: 10.1371/journal.pmed.1001455
Source DB: PubMed Journal: PLoS Med ISSN: 1549-1277 Impact factor: 11.069
Summary of major research gaps and needs for evidence on health outcomes.
| Health Topic | Major Gaps and Needs Identified |
| Cancer | • Determine the risk from coal-related HAP exposure on cancer of organ systems other than the lung.• Assess the risk from biomass-related HAP exposure for cancer of the lung, upper airway, and other organ systems.• Investigate whether risk is mediated via germline, somatic, or epigenetic changes and whether there is a developmental window of susceptibility. |
| Infections | • Carry out population-based studies to determine the impact on important infectious diseases, including TB and malaria (the latter via effects of smoke on biting and disease transmission), and the impacts of interventions.• Extend the experience of the RESPIRE study on acute child pneumonia to other populations and cultures and determine etiology (pathogens) and exposure–response relationships more precisely.• Leverage existing epidemiologic studies investigating pneumonia and the impacts of new vaccines by adding HAP exposure assessment. |
| Cardiovascular disease | • Use short- and longer-term observational studies (including those leveraging existing cohorts) and intervention studies to determine the risk of completed cardiovascular outcomes, indicators of disease process (e.g., ECG findings), and risk (e.g., blood pressure, lipid levels, inflammatory biomarkers).• Determine the role of HAP in the developmental origins of CVD through long-term cohort studies. |
| Maternal, neonatal, and child health | • Strengthen existing evidence on pregnancy outcomes (pre-term birth, IUGR, stillbirth), with assessment of gestational age and vulnerable periods of exposure during pregnancy.• Investigate the risk of severe infection in neonates and young infants.• Strengthen emerging evidence on child growth and cognitive development to 5–7 years of age.• Determine the risk of HAP exposure for the main causes of maternal mortality and morbidity.• Establish long-term cohorts to study the role of early HAP exposure and associated mechanisms (including epigenetic) in the developmental origins of later childhood and adult disease. |
| Respiratory disease | • Use cohort studies and clinical trials to determine the roles of HAP in both causation and exacerbation of asthma in children.• Assess the impacts of HAP exposure reduction on the rate of lung function decline over the medium term (e.g., 5 years) in young/middle-aged women.• Describe the risks of HAP exposure in pregnancy and early life for lung development, asthma, and COPD. |
| Burns | • Enhance surveillance and population-based evidence on the causes, incidence and mortality, disability, and longer-term social impacts of burn injuries.• Assess the impact of safety testing of new stoves.• Determine the value of prevention strategies on morbidity and mortality related to burn injuries or accidental poisoning (e.g., with kerosene) from cooking, heating, and lighting. |
| Ocular disorders | • Extend the evidence on cataracts in men and in exposed populations outside of India.• Ensure better control of potentially serious confounding in studies of cataract (e.g., smoking, UV light exposure, nutrition).• Strengthen tentative evidence on risk for other important ocular disorders, such as trachoma.• Investigate the motivational potential of reduced eye symptoms (tearing, irritation) for intervention programs. |
CVD, cardiovascular disease; ECG, electrocardiogram; IUGR, intrauterine growth restriction; TB, tuberculosis; UV, ultraviolet.
Summary of major gaps and research needs for cross-cutting issues.
| Health Topic | Major Gaps and Needs Identified |
| Exposure and biomarkers | • Better characterize spatial and temporal variability in exposures to HAP by studying critical behavioral patterns and individual- and household-level characteristics.• Further develop and field test small/light and highly time-resolved personal monitors for particulate matter and other important pollutants (e.g., size-specific and chemical constituents of particulate matter, carbon monoxide).• Develop standardized and comprehensive exposure-assessment protocols (including questionnaires to understand critical factors in exposure variability), suitable for use with intervention-evaluation and epidemiologic studies.• Develop and validate methods to estimate dose, including biomarkers of exposure, especially for cumulative exposures.• Assess the role of validated biomarkers of early effect or early disease activity in studies of chronic disease. |
| Women's empowerment | • In research and evaluation, include sex-disaggregated analysis and pay attention to gender dimensions of behaviors that affect the uptake of clean cooking interventions and the health risks associated with fuel collection.• In epidemiologic studies on health outcomes, recognize that women may not access health services with the same frequency as men, resulting in bias in studies from clinics and hospitals.• Assess the potential educational and economic benefits of improved stoves or fuels that provide more free time and reduced health risks for women and girls. |
| Behavioral change | • Ensure that behavioral research plays a more central role in stove and program design to optimize the safe and exclusive use of new stoves and clean fuels to minimize exposure and burn risks.• Evaluate behavior-change interventions for proper and exclusive use of improved stoves and fuels, exposure reductions, and safety improvements. |
| Program evaluation | • Strengthen cooperation between investigators and implementers to develop more appropriate study designs using standardized methods for assessing health impacts.• Make the results of evaluation available as rapidly as possible and in a manner that encourages widespread learning and quality improvement. |
Figure 1HAP in urban and rural settings with examples of other confounding sources of pollutants.
Multiple factors influencing household air pollution and personal exposure levels need to be considered for effective measurement of exposure in health research and evaluation studies, which will differ in urban vs. rural settings and may vary based on cultural practices, geography, and elevation. Each site of HAP must be carefully assessed for other potential sources of products of incomplete combustion that may confound household or personal monitoring of exposure.
Approaches and key study designs required to address research and evaluation priorities.
| Nature of Research and Evaluation | Study Designs/Data Collection Methods | Examples of Research Areas for Which Approach Would Be Appropriate |
| Investigator initiated | Cohort studies (short term) | Risks of exposure for pregnancy outcomes, birth weight, and diseases in the neonate and young child; mechanisms |
| Cohort studies (longer term) | Child growth and development, with follow-up into adulthood; chronic disease; developmental origins of adult disease | |
| Case control | Etiological studies, especially of rarer events (e.g., severe outcomes and mortality, congenital abnormalities) and chronic, longer-latency outcomes (e.g., cancer, IHD, eye disease, TB, CVD) | |
| Intervention: randomized including cluster and step-wedge designs | Impacts of interventions on mainly short-term outcomes and longer-term effects of differential exposure in pregnancy and early life, including pregnancy outcomes, child pneumonia, burns, and risk factors for chronic disease | |
| Evaluation of implementation programs | Intervention: quasi-experimental | Earlier stages of implementation, e.g., impacts on HAP, exposure, burns |
| Matched comparisons (randomization unlikely to be compatible with program implementation) | Shorter- to medium-term health outcomes | |
| Case control | Shorter- to medium-term health outcomes as programs reach scale | |
| Routine data collection and surveillance | Surveillance | Shorter- to medium-term health outcomes as programs reach scale |
| Registries | Etiological studies and evaluation of larger-scale interventions |
CVD, cardiovascular disease; IHD, ischemic heart disease; TB, tuberculosis;